Physiogenex
  • About Us
    • Company overview
    • Management Team
    • Our values
    • Facilities
    • Partners
  • CRO Services
    • In vitro assays
    • Obesity – Insulin Resistance – Diabetes
    • NASH/MASH/MetALD Fibrosis
    • Diabetic Nephropathy/CKD
    • Fibrosis
    • Diabetic Neuropathy
    • GLP-1 Expertise
    • Immunometabolism
    • Dyslipidaemia Atherosclerosis
    • Nutraceuticals
    • Covid-19
  • Capabilities
    • In vivo metabolic studies
    • Ex vivo metabolic assays
    • Biochemical assays and histology analysis
    • Biological samples library
  • Consulting
  • Publications
  • News
  • careers
    • Spontaneous Application
    • Careers at Physiogenex
  • Contact us
Select Page
Physiogenex to present its obese NASH hamster model for severe COVID-19 at the 19th WCIRDC in Los Angeles, CA, USA

Physiogenex to present its obese NASH hamster model for severe COVID-19 at the 19th WCIRDC in Los Angeles, CA, USA

by François Briand | Nov 24, 2021 | 2021, News

Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 19th World Congress of Insulin Resistance, Diabetes &...
Physiogenex to present its 3-week NASH mouse model at the 7th Paris NASH meeting

Physiogenex to present its 3-week NASH mouse model at the 7th Paris NASH meeting

by François Briand | Sep 7, 2021 | 2021, News

Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 7th Paris NASH Meeting Sept. 9-10 2021, Paris, France....
Physiogenex to present a new NASH mouse study at the 8th Aging Research and Drug Discovery (ARDD) meeting

Physiogenex to present a new NASH mouse study at the 8th Aging Research and Drug Discovery (ARDD) meeting

by François Briand | Aug 26, 2021 | 2021, News

Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 8th Aging Research Drug Discovery (ARDD), Aug. 31st –...
Physiogenex appoints Dr. Estelle Grasset as Project Manager – Research & Development

Physiogenex appoints Dr. Estelle Grasset as Project Manager – Research & Development

by François Briand | Jun 3, 2021 | 2021, News

Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), announced the appointment of Estelle Grasset, PhD in Biology and Biotechnology, as...

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH/MASH fibrosis, dyslipidemia, inflammation, diabetic nephropathy and cardiovascular complications. For > 15 years, we have been evaluating the drugs’ efficacy of our clients using gold-standard and radio-tracer based experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated with our numerous co-publications with our industry partners.

For more information on our company and offers, please download our Corporate Presentation.

Menu

  • CRO Services
  • Consulting
  • Publications
  • News
  • Careers

Services

  • Obesity – Diabetes
  • Dyslipidaemia Atherosclerosis
  • NASH/MASH/MetALD Fibrosis
  • Diabetic Nephropathy/CKD
  • Nutraceuticals

Useful Menu

  • Accueil
  • Contact us
  • Site map
  • Legal mentions
  • Privacy Policy

Contact

PHYSIOGENEX S.A.S.

Address : 280 rue de l’Hers, ZAC de la Masquère, 31750 Escalquens – France
Phone : +33532097980

For general inquiries, please contact us here.

  • X
  • RSS
Copyright © PHYSIOGENEX
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.Accept Reject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT